Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
泰福资本 (TF Capital) is a venture capital firm founded in 2013 and headquartered in Shanghai, China. The firm specializes in partnering with early-stage innovators in the biotechnology sector, managing approximately $1 billion in assets under management (AUM). TF Capital has established a global focus, identifying and nurturing promising biotech companies worldwide. The firm has built a diverse portfolio that includes over 116 companies and has facilitated 20 initial public offerings (IPOs).
Since its inception, TF Capital has evolved to become a significant player in the biotech investment landscape. The firm emphasizes a full value-chain support approach, leveraging its extensive biopharmaceutical networks and partnerships with clinical experts and investment funds. This strategy enables TF Capital to support global expansion efforts and foster innovation across its portfolio companies.
TF Capital's notable milestones include its consistent investment activity, with a portfolio that spans various stages of development, from pre-seed to Series C. The firm is strategically positioned to capitalize on the growing demand for innovative healthcare solutions, particularly in the biopharmaceutical sector.
TF Capital primarily invests in the biotechnology sector, targeting early-stage companies that are engaged in drug discovery and biomedical technology. The firm focuses on various stages of investment, including pre-seed, seed, seed-plus, Series A, Series B, and Series C. This broad investment range allows TF Capital to support companies at different points in their development, providing the necessary capital and strategic expertise to facilitate growth.
The firm emphasizes a full value-chain support approach, leveraging its extensive biopharmaceutical networks and partnerships with clinical experts and investment funds. TF Capital seeks to foster innovation and strengthen cross-regional collaboration, particularly in key biopharma hubs globally. The firm looks for founders who demonstrate a strong vision, commitment to their projects, and the ability to navigate the complexities of the biotech landscape.
TF Capital's portfolio includes a diverse array of companies, showcasing its commitment to the biotechnology sector. Notable companies in its portfolio include:
K. Chiang: Founding & Managing Partner. K. Chiang has extensive experience in venture capital and biotechnology, having led numerous successful investments in the sector. His background includes roles at leading investment firms and a strong track record in identifying promising biotech innovations.
Wei Cheng: Partner. Wei Cheng brings a wealth of knowledge in biopharmaceutical investments and has been instrumental in building TF Capital's portfolio. His expertise lies in strategic planning and operational support for portfolio companies.
To pitch TF Capital, founders should send an email to info@tfcapital.net. It is essential to include a comprehensive pitch deck that outlines the business model, market opportunity, and financial projections. The firm appreciates clear and concise presentations that effectively communicate the startup's vision and potential.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review process.
In February 2026, TF Capital made a significant investment in Angitia Biopharmaceuticals, further expanding its portfolio in the biotech sector. Earlier in March 2023, the firm participated in a $50 million Series B round for Allorion Therapeutics, showcasing its active engagement in funding innovative biotech companies.
TF Capital has consistently demonstrated its commitment to the biotechnology sector, with a total of 116 investments to date. The firm continues to seek out promising opportunities in the global market, particularly in the biopharma space.
What are TF Capital's investment criteria?
TF Capital primarily invests in early-stage biotechnology companies, focusing on drug discovery and biomedical technology. The firm targets various stages of investment, including pre-seed, seed, seed-plus, Series A, Series B, and Series C.
How can I apply or pitch to TF Capital?
Founders can pitch to TF Capital by sending an email to info@tfcapital.net. It is advisable to include a detailed business plan and financial projections in the pitch deck.
What makes TF Capital different from other venture capital firms?
TF Capital distinguishes itself through its extensive networks in the biopharmaceutical industry and its commitment to providing comprehensive capital support and strategic expertise to its portfolio companies.
What is TF Capital's geographic scope?
TF Capital has a global focus, with particular attention to key biopharma hubs in Asia and beyond. The firm actively seeks promising biotech innovations worldwide.
What is TF Capital's post-investment involvement like?
TF Capital is known for its active involvement in the growth of its portfolio companies, providing operational support, strategic guidance, and access to its extensive network of industry contacts.
What is the typical check size for investments?
While specific check sizes are not disclosed, TF Capital invests across a range of stages, indicating flexibility in its investment amounts based on the needs of the company.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.